Jagsonpal Pharmaceuticals (BOM:507789) Cyclically Adjusted Revenue per Share: ₹37.33 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:507789 Jagsonpal Pharmaceuticals Ltd BOM:507789
72 GF Score
Price ₹226.80
GF Value ₹218.12
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Jagsonpal Pharmaceuticals Cyclically Adjusted Revenue per Share?

Jagsonpal Pharmaceuticals BOM:507789 -1.20% 72 Cyclically Adjusted Revenue per Share is ₹37.33 as of Jun. 2026. GuruFocus rates BOM:507789 with a GF Score™ of 72/100 and a GF Value™ of ₹218.12 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Jagsonpal Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹12.345. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹37.33 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Jagsonpal Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 6.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Jagsonpal Pharmaceuticals was 4.40% per year. The lowest was 2.30% per year. And the median was 3.30% per year.

As of today (2026-08-17), Jagsonpal Pharmaceuticals's current stock price is ₹226.80. Jagsonpal Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹37.33. Jagsonpal Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 6.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jagsonpal Pharmaceuticals was 8.88. The lowest was 0.46. And the median was 4.41.


Jagsonpal Pharmaceuticals  (BOM:507789) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Jagsonpal Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=226.80/37.33
=6.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jagsonpal Pharmaceuticals was 8.88. The lowest was 0.46. And the median was 4.41.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Jagsonpal Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Jagsonpal Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Jagsonpal Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jagsonpal Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Jagsonpal Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.19 32.16 32.99 34.43 36.62

Jagsonpal Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.12 35.98 36.46 36.62 37.33

BOM:507789 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jagsonpal Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jagsonpal Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jagsonpal Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Jagsonpal Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BOM:507789
72GF Score
Jagsonpal Pharmaceuticals Ltd BOM:507789
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jagsonpal Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jagsonpal Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=12.345/167.3573*167.3573
=12.345

Current CPI (Jun. 2026) = 167.3573.

Jagsonpal Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 6.043 105.961 9.544
201612 5.249 105.196 8.351
201703 4.463 105.196 7.100
201706 4.104 107.109 6.412
201709 4.411 109.021 6.771
201712 5.826 109.404 8.912
201803 4.996 109.786 7.616
201806 6.530 111.317 9.817
201809 6.781 115.142 9.856
201812 6.437 115.142 9.356
201903 5.853 118.202 8.287
201906 6.863 120.880 9.502
201909 6.346 123.175 8.622
201912 6.403 126.235 8.489
202003 4.512 124.705 6.055
202006 4.823 127.000 6.356
202009 8.603 130.118 11.065
202012 8.707 130.889 11.133
202103 6.508 131.771 8.266
202106 8.241 134.084 10.286
202109 8.932 135.847 11.004
202112 8.233 138.161 9.973
202203 7.811 138.822 9.417
202206 9.294 142.347 10.927
202209 9.231 144.661 10.679
202212 9.177 145.763 10.537
202303 8.469 146.865 9.651
202306 9.169 150.280 10.211
202309 8.792 151.492 9.713
202312 7.187 152.924 7.865
202403 6.579 153.035 7.195
202406 8.877 155.789 9.536
202409 10.299 157.882 10.917
202412 10.968 158.323 11.594
202503 8.718 157.552 9.261
202506 11.067 159.755 11.594
202509 11.074 162.289 11.420
202512 10.991 163.281 11.265
202603 8.866 164.272 9.032
202606 12.345 167.357 12.345

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹37.33 mean?
Jagsonpal Pharmaceuticals (BOM:507789) has a Cyclically Adjusted Revenue per Share of ₹37.33 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jagsonpal Pharmaceuticals and its competitors.
Is Jagsonpal Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Jagsonpal Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹37.33. Overall, Jagsonpal Pharmaceuticals has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jagsonpal Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
Jagsonpal Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹37.33 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jagsonpal Pharmaceuticals and its competitors. Jagsonpal Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹37.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jagsonpal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals (BOM:507789) is currently considered Fairly Valued. The stock's GF Value™ is ₹218.12, compared to a current price of ₹226.80 — trading 4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹37.33. Jagsonpal Pharmaceuticals' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Jagsonpal Pharmaceuticals (BOM:507789), the current Cyclically Adjusted Revenue per Share is ₹37.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jagsonpal Pharmaceuticals (BOM:507789) Overvalued in 2026?

Based on GuruFocus' analysis, Jagsonpal Pharmaceuticals stock appears to be overvalued. The current stock price of ₹226.80 is trading 4% above its estimated GF Value™ of ₹218.12. GuruFocus considers Jagsonpal Pharmaceuticals to be Fairly Valued.

Key valuation signals for BOM:507789:

  • Cyclically Adjusted Revenue per Share: ₹37.33
  • GF Value™: ₹218.12 vs. price of ₹226.80 (4% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the BOM:507789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jagsonpal Pharmaceuticals Business Description

Other Exchanges JAGSNPHARM:India
Address 3rd Floor, Phase - IV, Udyog Vihar, Plot No. 412-415, Nimai Tower, Gurugram, HR, IND, 122015
Jagsonpal Pharmaceuticals Ltd is a pharmaceutical company. It develops and manufactures active pharmaceutical ingredients and formulations like Capsule and Tablet. The company operates in the Gynaecology, Orthopaedics, Dermatology and Paediatric segments. Its brands comprise Lycored, Maintane, Doxypal DR, and others.
72GF Score

Get the complete analysis for BOM:507789

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹226.80
Price
₹218.12
GF Value